Posters

Safety and efficacy of ab-interno canaloplasty (ABiC) for the treatment of open-angle glaucoma

Poster Details

First Author: M. Khaimi UNITED STATES

Co Author(s):                        

Abstract Details

Purpose:

To investigate the safety and efficacy of ABiC in reducing IOP and glaucoma medication dependence in OAG

Setting:

Dean McGee Eye Institute, University of Oklahoma, Oklahoma City, Oklahoma, United States of America

Methods:

This nonrandomized, single center study explored the effect of ABiC or combined cataract surgery-ABiC in adult OAG patients. The primary endpoints included mean IOP and mean number of glaucoma medications over a 12-month period. Secondary endpoints included surgical/postsurgical complications and secondary interventions.

Results:

Cohort included 106 subjects with a baseline mean IOP of 19.5 ± 6.6 mmHg which reduced to 15.7 ± 4.4 mm Hg (n=69), 15.0 ± 3.8 mm Hg (n=69), 13.9 ± 1.9 mm Hg (n=20) at 3, 6, 12 months postoperative, respectively. Medication dependency reduced from 2 ± 1 drops preoperatively to 0 ±1 drops at 3, 6, 12 months postoperative, representing a total average decrease of 28.7% in IOP and 100% in medications at 12 months postoperative, versus baseline. In the group of patients who underwent standalone ABiC, mean IOP was reduced by 36.8% from 22.0 ± 8.2 mm Hg preoperatively (n=38) to 13.9 ± 1.6 mm Hg at 12 months postoperative (n=8) with a 50% reduction in medication.

Conclusions:

ABiC is safe and effective in achieving IOP reduction and reduces dependence on anti-glaucoma medications in patients with OAG, both as a standalone procedure and combined with phacoemulsification.

Financial Disclosure:

NONE